FI119191B - Bifunktionaalinen proteiini, valmistus ja käyttö - Google Patents

Bifunktionaalinen proteiini, valmistus ja käyttö Download PDF

Info

Publication number
FI119191B
FI119191B FI964311A FI964311A FI119191B FI 119191 B FI119191 B FI 119191B FI 964311 A FI964311 A FI 964311A FI 964311 A FI964311 A FI 964311A FI 119191 B FI119191 B FI 119191B
Authority
FI
Finland
Prior art keywords
gly
ser
thr
leu
gin
Prior art date
Application number
FI964311A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964311A0 (fi
FI964311A (fi
Inventor
Bernd Groner
Dirk Moritz
Original Assignee
Bernd Groner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernd Groner filed Critical Bernd Groner
Publication of FI964311A0 publication Critical patent/FI964311A0/fi
Publication of FI964311A publication Critical patent/FI964311A/fi
Application granted granted Critical
Publication of FI119191B publication Critical patent/FI119191B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
FI964311A 1994-05-02 1996-10-25 Bifunktionaalinen proteiini, valmistus ja käyttö FI119191B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94810244 1994-05-02
EP94810244 1994-05-02
EP9501494 1995-04-20
PCT/EP1995/001494 WO1995030014A1 (fr) 1994-05-02 1995-04-20 Proteine a double fonction, sa preparation et son utilisation

Publications (3)

Publication Number Publication Date
FI964311A0 FI964311A0 (fi) 1996-10-25
FI964311A FI964311A (fi) 1996-10-25
FI119191B true FI119191B (fi) 2008-08-29

Family

ID=8218248

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964311A FI119191B (fi) 1994-05-02 1996-10-25 Bifunktionaalinen proteiini, valmistus ja käyttö

Country Status (18)

Country Link
US (1) US6984382B1 (fr)
EP (1) EP0758394B1 (fr)
JP (1) JP3742103B2 (fr)
KR (1) KR100373813B1 (fr)
AT (1) ATE228166T1 (fr)
AU (1) AU694222B2 (fr)
CA (1) CA2188422C (fr)
DE (1) DE69528894T2 (fr)
DK (1) DK0758394T3 (fr)
ES (1) ES2185705T3 (fr)
FI (1) FI119191B (fr)
IL (1) IL113530A0 (fr)
NO (1) NO316923B1 (fr)
NZ (1) NZ285395A (fr)
PT (1) PT758394E (fr)
TW (1) TW428026B (fr)
WO (1) WO1995030014A1 (fr)
ZA (1) ZA953440B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ285395A (en) 1994-05-02 1998-10-28 Novartis Ag Chimeric antibody, cancer treatment
WO1997024446A2 (fr) * 1995-12-29 1997-07-10 Chiron Corporation Ligands de ciblage de vehicules pour l'apport de genes
WO1998012227A1 (fr) * 1996-09-19 1998-03-26 Diagnocure Inc. Anticorps de recombinaison a chaine unique agissant contre le marqueur gp54 du cancer, composition les contenant et leur mode d'utilisation
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE10121113A1 (de) * 2001-04-28 2002-10-31 Gabriele Pecher Genmodifizierte YT Zelllinie und ihre Verwendung
CA3052445C (fr) 2004-07-10 2023-08-22 Kerry S. Campbell Lignees de cellules tueuses, naturelles, humaines et genetiquement modifiees
WO2006036445A2 (fr) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Recepteur nk chimerique et traitement anticancereux
PL1912675T3 (pl) 2005-07-25 2014-10-31 Emergent Product Dev Seattle Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
NZ596865A (en) * 2006-06-12 2013-07-26 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
US20100105136A1 (en) * 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (fr) 2009-10-29 2011-05-19 Trustees Of Dartmouth College Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
DK2649086T3 (en) 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
EP3744736A1 (fr) 2013-02-20 2020-12-02 Novartis AG Ciblage efficace de la leucémie primaire humaine au moyen de lymphocytes t génétiquement modifiés des récepteurs d'antigènes chimériques anti-cd123
BR112015019603A2 (pt) 2013-02-20 2017-08-22 Novartis Ag Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
EP2970426B1 (fr) 2013-03-15 2019-08-28 Michael C. Milone Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗-cd19嵌合抗原受體治療癌症
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015090229A1 (fr) 2013-12-20 2015-06-25 Novartis Ag Récepteur d'antigène chimérique régulable
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
JP6765966B2 (ja) 2014-04-07 2020-10-07 ノバルティス アーゲー 抗cd19キメラ抗原受容体を使用する癌の処置
WO2016014553A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
CA2955465A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Traitement du cancer au moyen d'un recepteur d'antigenes chimeriques cll-1
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
LT3183268T (lt) 2014-08-19 2020-06-10 Novartis Ag Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
JP6815992B2 (ja) 2014-10-08 2021-01-20 ノバルティス アーゲー キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
RU2021118125A (ru) 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (fr) 2015-02-02 2016-08-11 Novartis Ag Cellules exprimant car dirigées contre de multiples antigènes tumoraux et leurs utilisations
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
CA2982996A1 (fr) 2015-04-17 2016-10-20 David Maxwell Barrett Procedes pour ameliorer l'efficacite et l'expansion de cellules exprimant un recepteur antigenique chimerique
TW201708538A (zh) 2015-07-21 2017-03-01 諾華公司 改良免疫細胞之功效及擴展之方法
EP3331913A1 (fr) 2015-08-07 2018-06-13 Novartis AG Traitement du cancer à l'aide des protéines de récepteur cd3 chimères
WO2017040930A2 (fr) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarqueurs prédictifs du syndrome de libération de cytokines
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
EP4043485A1 (fr) 2017-01-26 2022-08-17 Novartis AG Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique
EP3589295A4 (fr) 2017-02-28 2020-11-04 Endocyte, Inc. Compositions et méthodes de thérapie par lymphocytes t car
RU2019133280A (ru) 2017-03-22 2021-04-22 Новартис Аг Композиции и способы для иммуноонкологии
WO2019144095A1 (fr) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Procédés d'utilisation de cellules t car
MX2020013443A (es) 2018-06-13 2021-02-26 Novartis Ag Receptores de antigeno quimerico de bcma y usos de los mismos.
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
WO2020043899A1 (fr) 2018-08-31 2020-03-05 Invectys Récepteurs d'antigènes chimériques contre de multiples isoformes de hla-g
TW202134285A (zh) 2019-11-26 2021-09-16 瑞士商諾華公司 Cd19和cd22嵌合抗原受體及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260880A3 (fr) 1986-09-11 1990-03-07 Dana-Farber Cancer Institute, Inc. Méthode de déclenchement de la cytotoxicité
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
FI105320B (fi) 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
EP0568537B1 (fr) 1990-10-31 1998-02-04 Somatix Therapy Corporation Modification genetique de cellules endotheliales
WO1992010591A1 (fr) * 1990-12-14 1992-06-25 Cell Genesys, Inc. Chaines chimeriques utilisees comme voies de transduction de signal associe a un recepteur
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
FR2672901B1 (fr) 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
WO1992015326A1 (fr) 1991-02-27 1992-09-17 The Regents Of The University Of California Immunogenicite a mediation par complexe de ciblage
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
WO1993019163A1 (fr) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Genes de recepteurs chimeres et cellules transformees au moyen desdits genes
AU2462392A (en) 1992-04-14 1993-11-18 British Biotech Pharmaceuticals Limited Induction of CTL responses
NZ285395A (en) 1994-05-02 1998-10-28 Novartis Ag Chimeric antibody, cancer treatment

Also Published As

Publication number Publication date
ATE228166T1 (de) 2002-12-15
NO316923B1 (no) 2004-06-28
PT758394E (pt) 2003-04-30
ES2185705T3 (es) 2003-05-01
US6984382B1 (en) 2006-01-10
FI964311A0 (fi) 1996-10-25
DE69528894T2 (de) 2003-03-27
EP0758394B1 (fr) 2002-11-20
CA2188422C (fr) 2011-03-15
CA2188422A1 (fr) 1995-11-09
AU694222B2 (en) 1998-07-16
NO964641L (no) 1996-11-01
DK0758394T3 (da) 2003-03-03
IL113530A0 (en) 1995-07-31
NZ285395A (en) 1998-10-28
WO1995030014A1 (fr) 1995-11-09
FI964311A (fi) 1996-10-25
KR100373813B1 (ko) 2003-10-08
JPH09512176A (ja) 1997-12-09
TW428026B (en) 2001-04-01
AU2446995A (en) 1995-11-29
JP3742103B2 (ja) 2006-02-01
ZA953440B (en) 1995-11-02
DE69528894D1 (de) 2003-01-02
NO964641D0 (no) 1996-11-01
EP0758394A1 (fr) 1997-02-19

Similar Documents

Publication Publication Date Title
FI119191B (fi) Bifunktionaalinen proteiini, valmistus ja käyttö
US11639387B2 (en) Bispecific chimeric antigen receptors, encoding polynucleotides thereof and methods of use thereof to treat disease
EP3313874B1 (fr) Lymphocytes t récepteurs antigéniques chimériques de masquage pour l'activation spécifique d'une tumeur
EP1012259B1 (fr) Vecteur ciblant les tumeurs
US7820174B2 (en) T cell receptors and related materials and methods of use
JP2002512502A (ja) 癌細胞の標的細胞溶解
CN112703206A (zh) 靶向肿瘤的重组双功能融合蛋白及其应用
US20240082400A1 (en) Cd64 chimeric receptor and uses thereof
US20230399402A1 (en) Hla class ii-restricted tcrs against the kras g12>v activating mutation
JP2003501402A (ja) 遺伝子治療用生成物
KR20010013219A (fr) Vecteur
Stancovski Tumor-inhibitory strategies directed at the HER-2/neu oncoprotein

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 119191

Country of ref document: FI

MM Patent lapsed